The recurrence rates of curettage alone are comparable to that of curettage with electrodessication in patients with keratinocyte carcinoma.

The loved ones of those with cancer report an emotional burden, including concerns about life expectancy, course of treatment, and pain.

The FDA has appointed George Francis Tidmarsh, MD, PhD, to be the director of the Center for Drug Evaluation and Research.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.

Intraclass biologic switching had better short-term efficacy in psoriasis, but both intraclass and interclass switching were effective long-term.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.